Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.35 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LOX | P28300 | 1/20 | 0.30 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.30 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7281196 | 0.79 | CA2 (0.43) | PTGS2LMNA | |
| SCHEMBL691616 | 0.79 | TTR (0.37) | — | |
| SCHEMBL1045336 | 0.79 | CA12 (0.41) | ALDH1A1LMNACYP1A2L3MBTL1 | |
| SCHEMBL5790937 | 0.78 | KDM4E (0.44) | RAB9AKDM4EALDH1A1PTGS2CCR2 | |
| SCHEMBL3835232 | 0.77 | L3MBTL1 (0.35) | ALDH1A1HSD11B1PTGS2BCAT2L3MBTL1 | |
| SCHEMBL3057169 | 0.77 | HSD11B1 (0.33) | HSD11B1BCAT2L3MBTL1LOX | |
| SCHEMBL6976387 | 0.77 | BCAT2 (0.33) | HSD11B1PTGS2BCAT2L3MBTL1LOX | |
| SCHEMBL1967430 | 0.75 | PTGS2 (0.32) | RAB9AKDM4EALDH1A1PTGS2CCR2 | |
| SCHEMBL10967866 | 0.75 | L3MBTL1 (0.38) | BCAT2LMNAL3MBTL1LOX | |
| SCHEMBL11567026 | 0.75 | CA1 (0.34) | BCAT2L3MBTL1LOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| EP-4017591-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2022-06-29 | — | — | EP | disclosed |
| EP-3774741-B1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2022-06-08 | — | — | EP | disclosed |
| US-20210094941-A1 | Antimalarial Hexahydropyrimidine Analogues | UCB Biopharma SRL (BE) | 2021-04-01 | — | — | US | disclosed |
| WO-2021032687-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2021-02-25 | — | — | WO | disclosed |
| EP-3774741-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2021-02-17 | — | — | EP | disclosed |
| US-20200101061-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2020-04-02 | — | — | US | disclosed |
| WO-2019192992-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB BIOPHARMA SPRL (BE) | 2019-10-10 | — | — | WO | disclosed |
| EP-3406596-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | Japan Tobacco Inc. (JP) | 2018-11-28 | — | — | EP | disclosed |
| US-20180265454-A1 | Method for Producing 4-Oxoquinoline Compound | JAPAN TOBACCO INC. (JP) | 2018-09-20 | — | — | US | disclosed |
| US-20090036684-A1 | METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1992607-A1 | METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND | Japan Tobacco, Inc. (JP) | 2008-11-19 | — | — | EP | disclosed |
| CN-100375742-C | 4-oxoquinoline compounds and utilization thereof as HIV integrase inhibitors | JAPAN TOBACCO INC (JP) | 2008-03-19 | — | — | CN | disclosed |
| US-7176220-B2 | 4-oxoquinoline compound and use thereof as pharmaceutical agent | JAPAN TOBACCO INC. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20060217413-A1 | 4-Oxoquinoline compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. | 2006-09-28 | — | — | US | disclosed |
| US-20060084665-A1 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-04-20 | — | — | US | disclosed |
| CN-1692101-A | 4-oxoquinoline compounds and utilization thereof as HIV integrase inhibitors | JAPAN TOBACCO INC (JP) | 2005-11-02 | — | — | CN | disclosed |
| US-20050239819-A1 | 4-Oxoquinoline compounds and utilization thereof as hiv integrase inhibitors | SHIONOGI & CO., LTD. (JP) | 2005-10-27 | — | — | US | disclosed |
| EP-1564210-A1 | 4-OXOQUINOLINE COMPOUNDS AND UTILIZATION THEREOF AS HIV INTEGRASE INHIBITORS | JAPAN TOBACCO INC. (JP) | 2005-08-17 | — | — | EP | disclosed |
| US-4176184-A | CARDIOTONICS, HYPOTENSIVES, ANTITHROMBOTICS AND ANTIARRHYTHMICS | BOEHRINGER INGELHEIM GMBH (DE) | 1979-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084665-A1 | Quinolizinone compound and use thereof as HIV integrase inhibitor | NQO2, ACE, CDK20 | RAB9A 1929/4885KDM4E 165/4885ALDH1A1 784/4885 |
| US-20200101061-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, CDKL4, IMPDH2 | RAB9A 3060/4885KDM4E 112/4885ALDH1A1 712/4885 |
| US-20210094941-A1 | Antimalarial Hexahydropyrimidine Analogues | G6PD, DPYD, DHODH | RAB9A 4385/4885KDM4E 1104/4885ALDH1A1 329/4885 |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, IMPDH2, DNTT | RAB9A 2870/4885KDM4E 92/4885ALDH1A1 717/4885 |
| US-20180265454-A1 | Method for Producing 4-Oxoquinoline Compound | IMPDH1, IMPDH2, CDK20 | RAB9A 2019/4885KDM4E 780/4885ALDH1A1 2769/4885 |
| US-20060217413-A1 | 4-Oxoquinoline compound and use thereof as HIV integrase inhibitor | IMPDH1, CDKL4, IMPDH2 | RAB9A 3293/4885KDM4E 148/4885ALDH1A1 703/4885 |
| US-20050239819-A1 | 4-Oxoquinoline compounds and utilization thereof as hiv integrase inhibitors | IMPDH1, IMPDH2, TYMP | RAB9A 3543/4885KDM4E 187/4885ALDH1A1 571/4885 |
| US-20090036684-A1 | METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND | IMPDH1, IMPDH2, CDK20 | RAB9A 2019/4885KDM4E 780/4885ALDH1A1 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.